Scarica l'app Stockscreener
99.21
0.31%
-0.31
Pre-mercato:
107.62
8.41
+8.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Citizens raises Protagonist Therapeutics stock price target on platform validation - Investing.com Canada
Protagonist Therapeutics: Q1 Earnings Snapshot - kare11.com
Protagonist Therapeutics, Inc. Q1 2026 Financial Report – SEC Filing, Balance Sheets, and Management Discussion - Minichart
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS - MarketBeat
Milestones and Takeda opt-out reshape Protagonist (NASDAQ: PTGX) outlook - Stock Titan
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist (NASDAQ: PTGX) posts Q1 profit amid ICOTYDE approval and $200M rusfertide opt-out - Stock Titan
Protagonist Therapeutics set to report as blockbuster bets grow - Investing.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MSN Money - MSN
Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock - Insider Monkey
331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC - MarketBeat
M&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
Vanguard shows 5.09% stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Pictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Vanguard reports 3.53M-share stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating - Moomoo
Blood cancer drug translates into $200 million payday for Bay Area company — and there's more to come - The Business Journals
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Moody Aldrich Partners LLC - MarketBeat
UBS Group AG Acquires 874,013 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
[ARS] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
Protagonist Therapeutics (NASDAQ: PTGX) plans 2026 meeting and expanded equity plan - Stock Titan
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
Takeda (TAK) and Protagonist Therapeutics Deal Revisited - GuruFocus
Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical - marketscreener.com
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration - Voice of Alexandria
Takeda takes U.S. rights to rusfertide; Protagonist eligible for $475M - Stock Titan
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics Shifts Focus to High Margin Commercial Royalties - HarianBasis.co
Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock - Yahoo Finance
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
CEO of Protagonist (NASDAQ: PTGX) makes bona fide share gift - Stock Titan
PTGX News | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
PTGX (Protagonist Therapeutics Inc.) rises 2.17 percent even as Q4 2025 EPS falls far below analyst consensus estimates.Profit Guidance - UBND thành phố Hải Phòng
How (PTGX) Movements Inform Risk Allocation Models - Stock Traders Daily
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight - GlobeNewswire Inc.
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) CFO Sells 1,750 Shares of Stock - MarketBeat
Protagonist Therapeutics CFO Ali Asif sells $184,572 in shares - Investing.com
Protagonist Therapeutics CFO Ali Asif sells $184,572 in shares By Investing.com - Investing.com Australia
Protagonist Therapeutics (NASDAQ: PTGX) CFO sells shares to cover RSU taxes - Stock Titan
PTGX (NASDAQ) Form 144: 1,750-share sale noted; insider disposals listed - Stock Titan
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Protagonist Therapeutics (PTGX) price target increased by 11.65% to 114.50 - MSN
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Two new hires get rights to 69,850 Protagonist shares in awards - Stock Titan
PTGX Maintained by Truist Securities -- Price Target Raised to $121 - GuruFocus
Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com
Polycythemia Vera Market: Rapid Increment Driven by Innovation - openPR.com
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $121 - Moomoo
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $112 - Moomoo
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):